Invetech helps bring bio-printers to life
11 December, 2009 by Staff WritersAustralian R&D firm delivers first of 3D bio-printer to Organovo using latter's NovoGen technology.
Clinuvel gets positive results for afamelanotide
10 December, 2009 by Tim DeanPilot study shows afamelanotide improves quality of life in cancer patients.
Australian biotech market watch 08/12/09
08 December, 2009 by Tim DeanCLS, Cochlear, ResMed, Ansell, Living Cell Technology, Ramsay Health Care, ChemGenex
Feature: Plumbing the peptides of spider toxins
03 December, 2009 by Graeme O'NeillFrench toxinologist, Pierre Escoubas, is finding interesting pharmacology in the venoms of smaller species that punch way above their weight.
Biotech Market Spotlight: Sonic Healthcare
02 December, 2009 by Tim DeanSonic Healthcare (ASX:SHL) continues its expansion strategy in the U.S.
QRxPharma kicks off pivotal trial for MoxDuo
02 December, 2009 by Tim DeanPhase III trial for MoxDuo IR in the U.S. with final trial to begin in 2010.
Feature: Microscopy in the third dimension
01 December, 2009 by Fiona WylieDr Nicole Bryce is applying her experience in 3-D imaging to see just how far fluorescent drugs can penetrate into live tumour-cell masses.
Australian biotech market watch 25/11/09
25 November, 2009 by Tim DeanPrima BioMed, QRxPHarma, Sirtex Medical, Primary Health Care, ResMed, Cochlear
FDA committee gives Pharmaxis tick of approval
23 November, 2009 by Tim DeanLung function test recommended for approval for us in the U.S. by FDA Pulmonary-Allergy Drugs Advisory Committee.
Prima BioMed developing oral cervical cancer vaccine
18 November, 2009 by Tim DeanPrima BioMed collaborating with Ian Frazer to develop new oral vaccine for human papillomavirus.
Australian biotech market watch 17/11/09
17 November, 2009 by Tim DeanPrima Biomed, Living Cell Technologies, Mesoblast, Sirtex, Ramsay Health Care
Prima Biomed in trading halt
17 November, 2009 by Tim DeanPrima Biomed shares halted pending announcement of oral vaccine for cervical cancer.
Biotech profile: NemGenix
17 November, 2009 by Tim DeanEarly-stage biotechnology companies were hardest hit by the GFC, but NemGenix has made it through by embracing every form of funding available.
Centre of Kinomics to open 'Pandora's box' of drug development
13 November, 2009 by Tim Dean$1 million Ramaciotti foundation award to create world's first centre to study kinomics.
Australian biotech market watch 11/11/09
11 November, 2009 by Tim DeanBiota Holdings, ChemGenex, pSividia, Patrys, Blackmores
